Defining optimal cut-off values and research methodology for evaluating systemic inflammatory markers in clinical outcome prediction.
Lye Mun
LM
Tho
Jae
J
Huh
Ian
I
Sanders
Ross
R
Carruthers
Sai
S
Han
Alexander
A
McDonald
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology*; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D006801:Humans; D008214:Lymphocytes / Q000473:pathology*; D008297:Male; D020360:Neoadjuvant Therapy; D009504:Neutrophils / Q000473:pathology*